Germany-based BioNTech is again cutting staff in Gaithersburg, Maryland, this time affecting 32 employees, according to a July 18 Worker Adjustment and Retraining Notification (WARN) Act notice. The layoffs at the biotech’s office and lab space at 25 West Watkins Mill Road are effective Sept. 16.
All entries for: Immune Diseases
July 21, 2025
BioNTech
Layoffs
Disease Area: Immune Diseases
Drug Type: Biologic, Small Molecule
July 17, 2025
GSK
Layoffs
London-based GSK is cutting its global research and development team by an unspecified number of people, Fierce Biotech reported July 15. A spokesperson told Fierce a “very limited number of positions will be impacted” across the company’s R&D workforce of more than 12,000 people.
Disease Area: Immune Diseases, Multiple, Oncology, Rare Diseases, Respiratory Diseases
Drug Type: Biologic, Small Molecule
July 10, 2025
KalVista Pharmaceuticals
Negative Outlook
While it is unclear how the IRA will be implemented, it will likely have a significant impact on the pharmaceutical industry and the pricing of prescription drug products.
Disease Area: Hematology, Immune Diseases, Multiple, Rare Diseases
Drug Type: Small Molecule
July 9, 2025
Jasper Therapeutics
Layoffs
After “issues” with a batch of its investigational antibody briquilimab “confounded” the readout of Jasper Therapeutics’ Phase Ib/IIa BEACON study in chronic spontaneous urticaria (CSU), the California-based biotech is laying off approximately half of its staff.
Disease Area: Chronic Disease, Hematology, Immune Diseases, Multiple
Drug Type: Biologic
July 8, 2025
Conduit Pharmaceuticals
Negative Outlook
On August 16, 2022, President Biden signed into the law the Inflation Reduction Act of 2022, or the IRA. Among other things, the IRA has multiple provisions that can impact the prices of drug products that are both sold into the Medicare program and throughout the United States. Beginning in 2023, a manufacturer of drugs covered by Medicare Parts B or D must pay a rebate to the federal government if their drug product’s price increases faster than the rate of inflation. This calculation is made on a drug product by drug product basis and the amount of the rebate owed to the federal government is directly dependent on the volume of a drug product that is paid for by Medicare Parts B or D. Additionally, starting for payment year 2026, CMS will negotiate drug prices annually for a select number of single source Part D drugs without generic or biosimilar competition. CMS will also negotiate drug prices for a select number of Part B drugs starting for payment year 2028. If a drug product is selected by CMS for negotiation, it is expected that the revenue generated from such drug will decrease.
Disease Area: Endocrinology, Immune Diseases, Multiple, Rare Diseases
Drug Type: Small Molecule
July 1, 2025
Bristol Myers Squibb
Layoffs
Princeton, NJ
10,001-50,000 employees
Bristol Myers Squibb continues to aim its cost-cutting measures at Lawrenceville, New Jersey, laying off 68 employees there, according to a Worker Adjustment and Retraining Notification notice. The pharma has now let go of 1,223 people in Lawrenceville since April 2024, including 874 team members this year. The latest cuts will occur in multiple waves starting Sept. 25 and end Jan. 15, 2026. BMS has its headquarters and a location housing its commercialization and late-stage development teams in Lawrenceville. It was not immediately clear if the latest layoffs affect both sites.
Disease Area: Cardiology, Hematology, Immune Diseases, Multiple, Oncology
Drug Type: Biologic, Small Molecule
June 25, 2025
Discontinued Research, Layoffs
Roughly a month after sharing that it would cut about half of its workforce, Leap Therapeutics has announced it will axe 75% of its staff over the next two months. The Cambridge, Massachusetts–based biotech is also winding down research and development activities and exploring strategic options that could include a sale, according to a June 23 SEC filing. The latest cuts affect 75% of the workforce, according to the filing, and will be carried out over two phases: one on or about June 30 and the second on or about July 31. The first round will include the departure of Augustine Lawlor, chief operating officer, while the second will include the exit of Cyndi Sirard, chief medical officer. Based on Leap having 52 full-time employees as of Dec. 31, according to its annual report, and the cuts detailed in a May 13 SEC filing, the company could have fewer than 10 staffers once the layoffs are complete.
Disease Area: Immune Diseases, Multiple, Oncology
Drug Type: Biologic
June 20, 2025
BioNTech
Discontinued Research, Layoffs
In conjunction with its decision to discontinue a study for one of its CAR T candidates, BioNTech will close down a cell therapy facility in Gaithersburg, Maryland, and lay off 63 employees at the site, according to a June 13 WARN notice and reporting from Fierce Pharma on Thursday.
Disease Area: Immune Diseases
Drug Type: Biologic, Small Molecule
June 12, 2025
Genentech
Layoffs
San Francisco, CA
10,001-50,000 employees
Laying off 143 workers at their headquarters in South San Francisco.
Disease Area: Cardiology, Immune Diseases, Multiple, Neurological Diseases, Oncology, Rare Diseases
Drug Type: Biologic, Small Molecule
May 25, 2025
AnaptysBio
Neutral Outlook
Thus, it is unclear how the IRA will be implemented but it will likely have a significant impact on the pharmaceutical industry and the pricing of our products and product candidates.
Disease Area: Dermatology, Gastrointestinal, Immune Diseases, Multiple, Oncology
Drug Type: Biologic
